Mona Maleknejadyazdi - Biology Department, University Jihad Unit, University of Science and Arts of Yazd, Iran.
Ali Akbar Haddad-Mashadrizeh - Department of Molecular and Cell Biology, Institute of Biotechnology, and Department of Ferdowsi University of Mashhad, Iran.

Immunotoxins have been used for cancer treatment. The immunotoxin binds to the surface antigen on the cancer cell, enters inside the cell by endocytosis۱, and destroys the cancer cell. In addition, the components of this type of drug and assembly based on peptide bonds۲, and the creation of recombinant protein construction were among the requirements investigated in this study. In this bioinformatics research, membrane antigen structural, and functional properties on the surface of breast cancer cells were investigated and evaluated to target cancer cells. An EGFR۳ antigen with a shorter amino acid length for positive binding and INS۴, which has ۱۱۰ amino acids, binding +, and a binding score of ۰.۹۹, was selected as the most efficient ligand using the AAASGG ۳ (GGGGS) linker۵, resulting in a six-recombinant structure. Hence, the targeted treatment of cancer through immunotoxin with the confirmation of the patent sequence led to the creation of a recombinant structure, which was analyzed with bioinformatics software. To ensure accurate results in the laboratory, we utilized Escherichia coli strain DH۵ as a host during the cloning phase for plasmid DNA replication. This enabled a more precise and reliable replication process, thereby confirming the validity of our computational modeling, and the results of this research led to the modeling and simulation of the engineering structure of Cetuximab ZZpe۳۸ immunotoxin. For future research, gene expression in mammalian cells will be the focus.

Breast cancer, Toxin, Ligand, EGFR antigens, Immunotoxin drug